



# A hemosztázis...

---

- *kórélettana és diagnosztikája* -

- *Dr. Tánczos Krisztián* -

*Aneszteziológiai és Intenzív Terápiás Intézet*



**XVI. Magyar Sürgősségi Orvostani Kongresszus**

*MSOTKE - MOT közös tudományos rendezvénye*

Siófok, 2017. november 16-18.



# Dinamikus szemlélet

---

- kritikus állapot -

Mérés


Értékelés

IDŐ


Kezelés

# Súlyos vérzés = oxigénadósság

Vincent JL et al. *Int. Care Med* 1990; 16:145–148




**ASSES**  
**Robert Wayne**  
 Departments of \*Em  
 University



J. 33, No. 2, pp. 113-122, 2010

**EGIES**

**in R. Ward\*†‡§**  
 ginia Commonwealth  
 nonwealth




|   |  |
|---|--|
| <p>Time 1<br/> <math>O_2</math> deficit = 30 mL min<sup>-1</sup><br/> <math>O_2</math> debt = 359 mL</p>  | <p>Time 2<br/> <math>O_2</math> deficit = 48 mL min<sup>-1</sup><br/> <math>O_2</math> debt = 912 mL</p> |
| <p>Time 3<br/> <math>O_2</math> deficit = 30 mL min<sup>-1</sup><br/> <math>O_2</math> debt = 1462 mL</p> | <p>Time 4<br/> <math>O_2</math> deficit = 0 mL min<sup>-1</sup><br/> <math>O_2</math> debt = 1871 mL</p> |



## ASSESSING SHOCK RESUSCITATION STRATEGIES BY OXYGEN DEBT REPAYMENT

**Robert Wayne Barbee,<sup>\*†§</sup> Penny S. Reynolds,<sup>\*§</sup> and Kevin R. Ward<sup>\*†‡§</sup>**


*Departments of <sup>\*</sup>Emergency Medicine, <sup>†</sup>Physiology, <sup>‡</sup>Biochemistry, and <sup>§</sup>Virginia Commonwealth University Reanimation Engineering Shock Center, Virginia Commonwealth University Medical Center, Richmond, Virginia*



## Lactate clearance as a predictor of mortality in trauma patients

Stephen R. Odom, MD, Michael D. Howell, MD, MPH, George S. Silva, BA, Victoria M. Nielsen, Alok Gupta, MD, Nathan I. Shapiro, MD, MPH, and Daniel Talmor, MD, MPH, Boston, Massachusetts


*J Trauma Acute Care Surg.* 2013;74:999-1004




## ASSESSING SHOCK RESUSCITATION STRATEGIES BY OXYGEN DEBT REPAYMENT

Robert Wayne Barbee,<sup>\*†§</sup> Penny S. Reynolds,<sup>\*§</sup> and Kevin R. Ward<sup>\*†‡§</sup>

Departments of <sup>\*</sup>Emergency Medicine, <sup>†</sup>Physiology, <sup>‡</sup>Biochemistry, and <sup>§</sup>Virginia Commonwealth University Reanimation Engineering Shock Center, Virginia Commonwealth University Medical Center, Richmond, Virginia



# A véralvadás alapjai...



Szöveti sérülés  
(Trauma, műtét)


Inflammáció  
(fertőzés, égés..)

Katekolamin

Endothél  
aktiváció

Primer hem

nolízis




Thro

na

**Hemorrhagic blood failure: Oxygen debt, coagulopathy, and endothelial damage**





*J Trauma Acute Care Surg. 2017;82:6,S41-49*



# Traumatic Endotheliopathy: A Prospective Observational Study of 424 Severely Injured Patients

*Pär I. Johansson, MD, DMSc, MPA,\*† Hanne H. Henriksen, BSc,\* Jakob Stensballe, MD, PhD,\*‡  
Mikkel Gybel-Brask, MD,\* Jessica C. Cardenas, PhD,† Lisa A. Baer, BSc,† Bryan A. Cotton, MD, MPH,†  
John B. Holcomb, MD,† Charles E. Wade, PhD,† and Sisse R. Ostrowski, MD, PhD, DMSc\**

*(Ann Surg 2017;265:597–603)*






# Shock induced endotheliopathy (SHINE) in acute critical illness - a unifying pathophysiologic mechanism

PärIngemar Johansson<sup>1,2,3\*</sup>, Jakob Stensballe<sup>1,4</sup> and SisseRye Ostrowski<sup>1</sup>

*Critical Care* (2017) 21:25 DOI 10.1186/s13054-017-1605-5






# Hemorrhagic blood failure: Oxygen debt, coagulopathy, and endothelial damage

*J Trauma Acute Care Surg.* 2017;82:6,S41-49


Nathan J. White, MD, MS, Kevin R. Ward, MD, Shibani Pati, MD, PhD,  
Geir Strandenes, MD, and Andrew P. Cap, MD, PhD



# Hemorrhagic blood failure: Oxygen debt, coagulopathy, and endothelial damage


*J Trauma Acute Care Surg.* 2017;82:6,S41-49

Nathan J. White, MD, MS, Kevin R. Ward, MD, Shibani Pati, MD, PhD,  
Geir Strandenes, MD, and Andrew P. Cap, MD, PhD







# Thrombocitafunkció

Zhang et al *J Neurotrauma* 2012; 29:2597–2605




# Multiple Electrode Aggregometry (MEA) Multiplate®




# Early Platelet Dysfunction: An Unrecognized Role in the Acute Coagulopathy of Trauma

Wohlauer et al. J Am Coll Surg. 2012; 214(5): 739–746



# Mérsékelt hipoperfúzió esetén....!





Sirajuddin et al. *J Trauma Acute Care Surg.* 2016;81: 328–332.

## Inhibition of platelet function is common following even minor injury

Sarah Sirajuddin, MD, Carrie Valdez, MD, Louis DePalma, MD, Patrick Maluso, MD, Rishi Singhal, Mary Schroeder, MD, and Babak Sarani, MD, Washington, District of Columbia

### METHODS:

A retrospective study of adult trauma patients evaluated at a Level I trauma center from August 2013 to September 2014 was conducted. Platelet function was assessed using TEG-PM. Patients on any anticoagulant or antiplatelet medication were excluded. Patients were divided into those with and without radiographically evident traumatic brain injury (TBI). Demographic variables, Injury Severity Score (ISS), injury pattern, laboratory test results, and mortality were abstracted. Statistical comparisons were made using the Student's *t* test or Mann-Whitney U-test.

### RESULTS:

The study includes 459 patients, 92% following blunt injury. Median ISS was 5. Patients with TBI ( $n = 102$ ) were significantly older (median age, 54 years vs. 35 years), were more severely injured (median ISS, 10 vs. 4), had a longer stay and higher mortality (9% vs. 0.3%). Maximal potential clot strength was normal in all cohorts, but the arachidonic acid and adenosine diphosphate pathways were significantly inhibited ( $30\% \pm 26\%$  and  $58\% \pm 27\%$ , respectively). There was no correlation between TEG-PM values and ISS, length of stay, or mortality. There was no difference in the TBI cohort. There were no significant differences in TEG-PM parameters in those with an ISS greater than 14. There was no significant change in TEG-PM following platelet transfusion.


### CONCLUSION:

Marked platelet inhibition is common following minor injury. Whereas the clinical significance of this finding remains unknown, the results of this study should be factored in the overall resuscitative strategy. (*J Trauma Acute Care Surg.* 2016;81: 328–332.)

# Hemorrhagic blood failure: Oxygen debt, coagulopathy, and endothelial damage

*J Trauma Acute Care Surg.* 2017;82:6,S41-49

Nathan J. White, MD, MS, Kevin R. Ward, MD, Shibani Pati, MD, PhD,  
Geir Strandenes, MD, and Andrew P. Cap, MD, PhD





# Hemorrhagic blood failure: Oxygen debt, coagulopathy, and endothelial damage

Nathan J. White, MD, MS, Kevin R. Ward, MD, Shibani Pati, MD, PhD,  
Geir Strandenes, MD, and Andrew P. Cap, MD, PhD

Thrombogenesis

Lysis



VÉRÁRAMLÁS


IM IM IM IM

Endothel cells




# Konvencionális tesztek

Bolliger D et al Transfusion Medicine Reviews 2012; 26: 1-13






# INR = 2.5 ?

Orális antikoagulánst  
(warfarint) szedő beteg



Kompenzált májcirrózisban  
szenvedő beteg (Child B)



Jobban vérzik


PCC terápia (FFP)  
(koponyasérült !!)

Nem vérzik jobban,  
DE: nincs tartaléka

FFP + PCC terápia

# Konvencionális tesztek

Bolliger D et al Transfusion Medicine Reviews 2012; 26: 1-13





Preoperatív

időszak

Folyadékre  
(2+2 E  
Nincs szerve

gázcsere  
vő  
in igény



Labor paraméter

INR

APTI

ATIII

TI

Fibrinogén

D-Dimer

Tct

1.54 ug/ml

107 G/l

Tranexámsav  
Fibrinogén + FFP

D-Dimer

Tct

érték

1.38

49.5 s

64 %

19.2 s


1.99 g/l

10.54 ug/ml

99 G/l

# Konvencionális tesztek

Bolliger D et al Transfusion Medicine Reviews 2012; 26: 1-13



Gyors – Dinamikus ?


# Konvencionális tesztek

## Functional definition and characterization of acute traumatic coagulopathy

Crit Care Med 2011 Vol. 39, No. 12

Ross Davenport, BSc, MD, MRCS; Joanna Manson, MD, MRCS; Henry De'Ath, MD, MRCS; Sean Platton, MSc, CSci, FIBMS; Amy Coates, BSc; Shubha Allard, MD, FRCP, FRCPath; Daniel Hart, MD; Rupert Pearse, MD, FRCA; K. John Pasi, PhD, FRCP, FRCPath, FRCPCH; Peter MacCallum, MD, FRCP, FRCPath; Simon Stanworth, DPhil, MRCP, FRCPath; Karim Brohi, FRCA, FRCS


***Main Results:* Three hundred patients were included in the study. Laboratory prothrombin time results were available at a median of 78 (62–103) mins.**



# Optimális alvadási teszt:

- súlyos vérzés esetén -

Gyors – Teljes vér - Dinamikus






# Viszkoelasztikus tesztek (TEG<sup>®</sup>, ROTEM<sup>®</sup>)

Bolliger D et al Transfusion Medicine Reviews 2012; 26: 1-13

Fast – Whole Blood - Dynamic





# Hemotherapy algorithm for the management of trauma-induced coagulopathy: the German and European perspective



**Curr Opin Anesthesiol** 2016, 29:000–000

---

*Marc Maegele<sup>a,b</sup>, Giuseppe Nardi<sup>c</sup>, and Herbert Schöchl<sup>d</sup>*

---


**ROTEM-based algorithm for the use of hemostatic agents and blood products  
during early trauma care**

| Recommendation | Interpretation  |
|----------------|---|
|                | <p data-bbox="792 336 920 368"><b>EXTEM</b></p>  <p data-bbox="824 496 1198 560">A10 &lt; 45 mm (A5 &lt; 35 mm) or<br/>MCF &lt; 55 mm</p> <p data-bbox="1294 336 1473 368"><b>FIBTEM</b></p>  <p data-bbox="1464 496 1825 560">A10 &lt; 10 mm (A5 &lt; 9 mm) or<br/>MCF &lt; 12 mm</p> |

# Hemorrhagic blood failure: Oxygen debt, coagulopathy, and endothelial damage


*J Trauma Acute Care Surg.* 2017;82:6,S41-49

Nathan J. White, MD, MS, Kevin R. Ward, MD, Shibani Pati, MD, PhD,  
Geir Strandenes, MD, and Andrew P. Cap, MD, PhD



# Structural Effects of Methionine Oxidation on Isolated Subdomains of Human Fibrin D and $\alpha$ C Regions

Patrick R. Burney<sup>1</sup>, Nathan White<sup>2</sup>, Jim Pfaendtner<sup>1\*</sup>




Weigandt et al. Biophysical Journal Volume (2012):2399–2407

# Post-translational oxidative modification of fibrinogen is associated with coagulopathy after traumatic injury



Free Radical Biology and Medicine 96 (2016) 181–189


Nathan J. White<sup>a,b,\*</sup>, Yi Wang<sup>b</sup>, Xiaoyun Fu<sup>b</sup>, Jessica C. Cardenas<sup>c</sup>, Erika J. Martin<sup>d</sup>, Donald F. Brophy<sup>d</sup>, Charles E. Wade<sup>c</sup>, Xu Wang<sup>a</sup>, Alexander E. St. John<sup>a</sup>, Esther B. Lim<sup>a</sup>, Susan A. Stern<sup>a</sup>, Kevin R. Ward<sup>e</sup>, José A. López<sup>b</sup>, Dominic Chung<sup>b</sup>





# Traumás diszfibrinogénémia



Konvencionális teszt  
fibrinogén szint: 2.2 g/l



Viszkoelasztikus teszt





# „Vérelégtelenség”





White NJ et al, J Trauma Acute Care Surg 2017;82, S41-49

1. Fizesd ki a...


2. Javítsd m...

3. Állítsd m...

4. Pótold,...




|              |           |                |
|--------------|-----------|----------------|
| <b>EXTEM</b> |           |                |
| CT: 59s      | CFT: 130s | $\alpha$ : 65° |
| A20: 47mm    | MCF: 48mm | ML: 100%       |





# „Vérelégtelenség”

White NJ et al, J Trauma Acute Care Surg 2017;82, S41-49



# Kezelési stratégia súlyosan vérző betegeknél

**Várható vvt. konc. szükséglet: > 4E/4 óra + hemodinamikai instabilitás +/- fennálló vérzés**

**Traumás eredet** (súlyos mellkasi, hasi, medence sérülés és/vagy többszörös hosszú csöves csont törés)

**Nem traumás eredet** (major szülészeti/gasztrointesztinális/sebészeti vérzés)

**Dinamikusan működő  
rendszer !**

## Laboratórium / Vérellátó Szolgálat

- a súlyosan vérző beteg mintái prioritást élveznek
- felkészül a nagyobb számú laborvizsgálat elvégzésére
- felkészül a várhatóan nagyobb mennyiségű vérkészítményigény kielégítésére
- a transzporthoz szükséges idő minimalizálása

## Transzfúziológus / Hematológus


- állandó kapcsolatot tart fenn az ellátást végző klinikusokkal
- értékeli a laboratóriumi vizsgálatok eredményeit
- segít a hemosztázis rendezésében

## Ellátást végző Klinikusok

- definitív vérzéscsillapítás

Vérzés ?


igen



# „Vérelégtelenség”


White NJ et al, J Trauma Acute Care Surg 2017;82, S41-49

## 1. Fizesd ki az oxigénadósságot!





## Advances in the understanding of trauma-induced coagulopathy

Ronald Chang,<sup>1,2</sup> Jessica C. Cardenas,<sup>1,2</sup> Charles E. Wade,<sup>1,2</sup> and John B. Holcomb<sup>1,2</sup>




# TEG/ROTEM curves...





2:

|            |      |
|------------|------|
| $\alpha$ : | 73°  |
| MCF:       | 14mm |






## THROMBOSIS AND HEMOSTASIS

**Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice**

Nuha Hijazi,<sup>1</sup> Rami Abu Fanne,<sup>1</sup> Rinat Abramovitch,<sup>2</sup> Serge Yarovoi,<sup>3</sup> Muhamed Higazi,<sup>1</sup> Suhair Abdeen,<sup>1</sup> Maamon Basheer,<sup>1</sup> Emad Maraga,<sup>1</sup> Douglas B. Cines,<sup>3</sup> and Abd Al-Roof Higazi<sup>1,3</sup>

**Key Points**

- Closed head trauma sequentially releases tPA followed by uPA from injured brain.
- Increased uPA is responsible for delayed intracerebral hemorrhage, which is prevented by a tPA variant that inhibits uPA activity.



# Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients



Hunter B Moore, MD, Ernest E Moore, MD, FACS, Ioannis N Liras, MD, Eduardo Gonzalez, MD, John A Harvin, FACS, MD, John B Holcomb, MD, FACS, Angela Sauaia, MD, PhD, Bryan A Cotton, MD, MPH, FACS

Vol. 222, No. 4, April 2016




Figure 3. Differences in causes of mortality between phenotypes.

Oxigénadósság

Vérgáz

Testhőmérséklet

Hematokrit

Súlyos trauma  
(ISS>16)

Rendezése

Hiperfibrinolízis

Laktát < 2 mmol/l, pH: >7,2

Testhőmérséklet: >34°C

Se. Kalcium: >1 mmol/l

Hematokrit: >24%

TXA: 15-20 mg/ttkg

1. Fibrinogén hiány

FIBTEM  
CA<sub>10</sub> < 7 mm

Fibrinogén komplex:

FIBTEM CA<sub>10</sub> 0-3 mm: 6g  
FIBTEM CA<sub>10</sub> 4-6 mm: 3-4 g

2. Trombingeneráció  
zavara

EXTEM  
CT > 80 sec

Faktor készítmény:

CT: 81s-100s: 500-600 E  
CT: 101s-120s: 1000-1200 E  
CT: >120s: 1500-1800 E

és/vagy FFP: 15-30 ml/ttkg

3. Thrombocita  
hiány

EXTEM CA<sub>10</sub> < 40 mm  
(ha FIBTEM CA<sub>10</sub> ≥ 12 mm)  
vagy trombocita szám  
< 50.000/μl

Thrombocita készítmény  
1 E/10 ttkg

4. Thrombocitopátia

ASPI teszt < 75 U  
ADP teszt < 53 U

DDAVP: 0,3 μg/ttkg

Súlyos  
alvadási zavar

EXTEM  
CA<sub>10</sub> < 30 mm

TXA: 15-25 mg/ttkg  
Fibrinogén komplex: 6-8 g  
Faktor készítmény: 20-30 E/ttkg  
vagy FFP: 30 ml/ttkg  
Trombocita konc.: 1 E/10 ttkg

# POCT diagnosztika (ACT, INR)

---

# Aktivált alvadási idő (ACT)

---

(Hattersley, 1966)

- az aPTT analógja

aPTT: citrátos (heparinos) vér + Ca + **kaolin**

ACT: natív (heparinos) vér + **kaolin** (+ testhő)

- Normál értéke 90-120 s (CPB:400-480 s)





# Prothrombin idő (INR)

---



| Teszt  | Normál érték  | Pozitív próba oka lehet pl.  |
|--|---|--|
| <p>Prothrombin idő (PT, Quick v. recalcificációs idő)</p> <p>Mivel a vizsgálandó plasma thromboplastinnal és phospholipiddel inkubált, Ca<sup>++</sup> adása után az alvadási folyamat „végigszalad” az extrinsic és a közös úton.</p> | <ul style="list-style-type: none"><li>· 12 s</li><li>· 100 % (prothrombin százalékos aktivitás)</li><li>· 1 (INR=beteg PT / ref.PT)</li></ul> | <p>Extrinsic alvadási trigger rendszer zavara, kumarin terápia</p> |




# TEG® vs. ROTEM®













2 E vvt






2 E vvt





2 E vvt  
 1 gr fibrinogén  
 8 E Tct  
 24 mikrogr DDAVP



# Esetismertetés

- 46 éves ffi, autóbaleset, stabil vitális paraméterek, GCS 15
- Diagnosztika: Hasi UH (3-4 cm szabad hasi folyadék)
- Anamnézis: vaszkulárisan dekompenzált májcirrózis (korábban: thr: 40-60G/L, INR: 1.51)


# Esetismertetés

- Obszerváció Traumatológiai osztályon (23:00)
- 05:54 - Periarrest állapot-reanimáció (6 perc)
  - ROSC és felvétel az ITO-ra
    - Elsődleges ellátás



# A mindennapokban...

---



Dr. Dietmar Fries: Basics of coagulation 2013; CSL Behring Symposium

Noradrenalin: 30 mcg/min

P: 115/min



RR: 106/32 Hgmm

Hőm. 33.1 C

Véralvadás  
szempontjából  
probléma:

|                 | 06:32 v | 06:35 a |
|-----------------|---------|---------|
| Hg (g/dL)       | 4.5     | 4.5     |
| Hct (%)         | 15      | 15      |
| pH              | 6.7     | 6.8     |
| PCO2 (Hgmm)     | 71.4    | 67.7    |
| PO2 (Hgmm)      | 25      | 151     |
| BE (mmol/L)     | -23.2   | -22.8   |
| cHCO3 ( mmol/L) | 9.4     | 8.9     |
| SO2 (%)         | 19      | 90      |
| Glu (mmol/L)    | 1.9     | 1.9     |
| Na (mmol/L)     | 148     | 149     |
| K (mmol/L)      | 5.4     | 5.3     |
| Ca (mmol/L)     | 0.75    | 0.74    |
| Lac (mmol/L)    | +++     | +++     |







**CT: máj körüli vérzés**



**Műtét! - De mikor?**

**3E vvt, NA, 60 mmol HCO<sub>3</sub>, 3g Ca, melegítés, 40g Glu,  
2g Exacyl, 3g Fibrinogén,  
4E FFP, 1000 E PPC,  
24 mcg DDAVP**





**8E vvt, NA, 100 mmol HCO<sub>3</sub>, melegítés,  
8E FFP, 500 PCC,  
24E Tct,**

# Dinamikus koagulációs menedzsment



Mérés




| Parameter                          | Value |
|------------------------------------|-------|
| ACT                                | 145   |
| APTT                               | 38    |
| PT                                 | 14.5  |
| INR                                | 1.1   |
| Fibrinogen                         | 4.8   |
| D-Dimer                            | 0.5   |
| Plasminogen                        | 100   |
| Plasminogen activator              | 0.5   |
| Plasminogen activator inhibitor    | 0.5   |
| Plasminogen activator inhibitor-1  | 0.5   |
| Plasminogen activator inhibitor-2  | 0.5   |
| Plasminogen activator inhibitor-3  | 0.5   |
| Plasminogen activator inhibitor-4  | 0.5   |
| Plasminogen activator inhibitor-5  | 0.5   |
| Plasminogen activator inhibitor-6  | 0.5   |
| Plasminogen activator inhibitor-7  | 0.5   |
| Plasminogen activator inhibitor-8  | 0.5   |
| Plasminogen activator inhibitor-9  | 0.5   |
| Plasminogen activator inhibitor-10 | 0.5   |
| Plasminogen activator inhibitor-11 | 0.5   |
| Plasminogen activator inhibitor-12 | 0.5   |
| Plasminogen activator inhibitor-13 | 0.5   |
| Plasminogen activator inhibitor-14 | 0.5   |
| Plasminogen activator inhibitor-15 | 0.5   |
| Plasminogen activator inhibitor-16 | 0.5   |
| Plasminogen activator inhibitor-17 | 0.5   |
| Plasminogen activator inhibitor-18 | 0.5   |
| Plasminogen activator inhibitor-19 | 0.5   |
| Plasminogen activator inhibitor-20 | 0.5   |

Értékelés

Dinamikus, individualizált kezelés !

Kezelés



# *Take Home Message*

## Complex coagulopathy and Time

### Viscoelastic test

(CT, CFT,  $\alpha$ , MCF, ML)

+

### Platelet aggregometry



### Conventional test

(I., II., III.,...XI., XII.,XIII,

PT, INR, aPTT, AT III,


fibrinogen, platelets count

FDP, D-dimer...)


**REVIEW**

# Point-of-care coagulation management in intensive care medicine

Patrick Meybohm, Kai Zacharowski\*, Christian F Weber




**Figure 1. Overview of coagulopathies typically present in critically ill patients.** DIC: disseminated intravascular coagulopathy; HIT: heparin-induced thrombocytopenia.



# Thrombocyta szám ≠ funkció


---







Procoagulation

Anticoagulation




# A mérés...





Hirudin vagy  
Heparin 40 perc






Aktivátor + 6 perc



3 perc




300  $\mu$ l of NaCl  
+ 300  $\mu$ l vér



# TEG® vs. ROTEM®

Solomon C et al BJA 2012; 109 (6): 851-63



**Table 1** Parameters recordable using TEG® and ROTEM®-based tests. \*G=(5000×MA)/(1

| Parameter recorded     | TEG® value             | ROTEM® value                  |
|------------------------|------------------------|-------------------------------|
| Coagulation initiation | r (reaction time)      | CT (clotting time)            |
| Clot formation         | k                      | CFT (clot formation time)     |
|                        | α° (alpha angle)       | α° (alpha angle)              |
| Clot strength/quality  |                        | A5, A10, A15, etc.            |
| Clot lysis             | MA (maximum amplitude) | MCF (maximum clot firmness)   |
|                        | G (clot rigidity)      | MCE (maximum clot elasticity) |
|                        | LY30 (lysis)           | LI30 (lysis index)            |
|                        |                        | MI (maximum lysis)            |

## Correlations with standard hemostatic laboratory tests

INR, aPTT, procoagulant factor levels

Fibrinogen, platelet count

Fibrinogen, platelet count

Fibrinogen, platelet count

Fibrin degradation products

Stravicz RT et al Gastroent & Hepat 2012; 8: 513-520


# Activators...

---

|            | Activation   | Sensitive                                     | Insensitive               |
|------------|--|---|---------------------------|
| RISTO test | <b>Ristocetin:</b> vWF dependens platelet activation via Gplb receptor       | Bernard-Soulier syndroma, severe vWD, aspirin |                           |
| COL test   | <b>Collagen:</b> platelet activation via GpIV and $\alpha 2\beta 1$ receptor | aspirin, IIb/IIIa antagonists                 | clopidogrel, vWF          |
| ASPI test  | <b>arachidon acid:</b> activation via COX - TXA <sub>2</sub> pathway         | aspirin, IIb/IIIa antagonist                  | clopidogrel, vWF          |
| ADP test   | <b>ADP:</b> ligand of platelet's ADP receptors                               | clopidogrel, IIb/IIIa antagonist              | aspirin, vWF              |
| TRAP test  | <b>TRAP-6</b> :thrombin receptor activating peptide                          | IIb/IIIa antagonista                          | vWF, aspirin, clopidogrel |

# Platelet aggregometry (Multiplate<sup>®</sup>)

Zhang et al *J Neurotrauma* 2012; 29:2597–2605



kirni



